Research has shown that glutathione (MaxGXL glutathione enhancer) helps stabilize the lung's response to inflammation in asthma models, while increasing the body's production of T-cells involved in immune response.
Scientists believe that glutathione might help the body naturally reduce the inflammatory response that leads to heightened allergy symptoms.
If you are one of the millions of individuals who enjoy spring and summer with some trepidation, relief might be closer than you think. The nutritional sciences are constantly discovering new ways to improve the quality of life without drugs and synthetic chemicals.
During an allergy attack, white blood cells produce billions of molecules that scour the body in search of mast cells.
Once they have been located, the two types combine to form one cell. Once this merger has occurred, they newly formed cells gradually begin to secrete histamine.
Quercetin (a component of MaxGXL) is a bioflavonoid that works by stabilizing mast cells, thus preventing them from releasing excess histamine into the bloodstream. It is histamine that promotes the sneezing, runny nose, watery eyes, and other symptoms associated with allergies. Stabilizing the cells that produce histamine has a powerful effect on how much histamine circulates throughout the body.
More on MaxGXL Glutathione: http://maxhealthproducts.net/
Sunday, May 18, 2008
Glutathione Helps Aids Survival
NEW YORK, March 03 (Reuters) -- Maintaining healthy levels of a peptide called glutathione may play a "pivotal" role in slowing the progression of AIDS, researchers say.
"People with HIV who have lower glutathione levels (also) have a much lower probability of surviving over the course of three years than do people with normal glutathione levels," concludes Stanford University School of Medicine geneticist Dr. Leonard Herzenberg.
Glutathione (GSH) is a molecule involved in a range of normal cell activities, including cell division and the clean-up of intracellular toxins. But a low glutathione level effectively "decreases cell survival, alters (immune system) T cell functions, and increases HIV replication" in HIV-infected cells, researchers say.
They add that GSH-level measurements may be an accurate marker of AIDS progression. Traditionally, physicians have assessed the condition of HIV-infected patients by measuring levels of CD4 cells, part of the immune-system. CD4 counts of 1,000 cells per milliliter (ml) of blood are normal in healthy, uninfected individuals. These numbers drop precipitously in those infected with HIV. CD4 levels under 200 cells/ml are thought to leave AIDS patients vulnerable to a number of life-threatening opportunistic infections.
Herzenberg's team divided 204 HIV-positive, (but AIDS-asymptomatic), patients into two groups. They gave one group glutathione and the other group a placebo.
Ninety-nine of the 204 Stanford study subjects had initial CD4 counts of under 200 cells/ml. Most of the 99 who received placebo (and thus maintained low glutathione levels) died within the three-year study period.
"In contrast," said Herzenberg, "of the 28 people who started the study with low CD4 counts but maintained normal glutathione levels, 23 survived. In other words, about 80% of these people survived, even though their CD4 cell counts indicated their survival was unlikely."
Herzenberg believes "glutathione levels matter to patient survival," and the study says clinical measurements of those levels "emerges as a powerful yardstick for predicting survival in HIV infection."
And Herzenberg believes that boosting GSH (glutathione) levels can keep AIDS patients healthier longer. The study "provides the first clear indication that GSH deficiency plays a pivotal role in determining how quickly the final stages of HIV disease progress." Herzenberg says clinical trials assessing impact of glutathione administration on long-term HIV patient survival is the next logical step in research on the subject.
SOURCE: Excerpts of the National Academy of Sciences (1997;94:1967-1972)
Learn more about Glutathione and MaxGXL at: http://maxhealthproducts.com/
"People with HIV who have lower glutathione levels (also) have a much lower probability of surviving over the course of three years than do people with normal glutathione levels," concludes Stanford University School of Medicine geneticist Dr. Leonard Herzenberg.
Glutathione (GSH) is a molecule involved in a range of normal cell activities, including cell division and the clean-up of intracellular toxins. But a low glutathione level effectively "decreases cell survival, alters (immune system) T cell functions, and increases HIV replication" in HIV-infected cells, researchers say.
They add that GSH-level measurements may be an accurate marker of AIDS progression. Traditionally, physicians have assessed the condition of HIV-infected patients by measuring levels of CD4 cells, part of the immune-system. CD4 counts of 1,000 cells per milliliter (ml) of blood are normal in healthy, uninfected individuals. These numbers drop precipitously in those infected with HIV. CD4 levels under 200 cells/ml are thought to leave AIDS patients vulnerable to a number of life-threatening opportunistic infections.
Herzenberg's team divided 204 HIV-positive, (but AIDS-asymptomatic), patients into two groups. They gave one group glutathione and the other group a placebo.
Ninety-nine of the 204 Stanford study subjects had initial CD4 counts of under 200 cells/ml. Most of the 99 who received placebo (and thus maintained low glutathione levels) died within the three-year study period.
"In contrast," said Herzenberg, "of the 28 people who started the study with low CD4 counts but maintained normal glutathione levels, 23 survived. In other words, about 80% of these people survived, even though their CD4 cell counts indicated their survival was unlikely."
Herzenberg believes "glutathione levels matter to patient survival," and the study says clinical measurements of those levels "emerges as a powerful yardstick for predicting survival in HIV infection."
And Herzenberg believes that boosting GSH (glutathione) levels can keep AIDS patients healthier longer. The study "provides the first clear indication that GSH deficiency plays a pivotal role in determining how quickly the final stages of HIV disease progress." Herzenberg says clinical trials assessing impact of glutathione administration on long-term HIV patient survival is the next logical step in research on the subject.
SOURCE: Excerpts of the National Academy of Sciences (1997;94:1967-1972)
Learn more about Glutathione and MaxGXL at: http://maxhealthproducts.com/
Subscribe to:
Posts (Atom)
